Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

NCT00345878 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

271

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: HPV-16/18 L1 VLP AS04 (Cervarix TM)

Sponsor

GlaxoSmithKline